Approach Considerations
Diagnosis of impetigo is usually based solely on history and clinical appearance. Bacterial culture and sensitivity are recommended (1) to identify possible methicillin-resistant Staphylococcus aureus (MRSA), (2) if an outbreak of impetigo has occurred, or (3) if poststreptococcal glomerulonephritis is present. Evidence of previous streptococcal skin infection may be sought in individuals in whom acute poststreptococcal glomerulonephritis (APSGN) is suspected.
In patients with nonbullous lesions, after cleansing the honey-colored crusted lesion and uplifting the scab, a bacterial culture of the fresh exudate underneath the scab may be obtained. In patients with bullous lesions, Gram stain and culture of the blister fluid is performed. On Gram stain, the presence of gram-positive cocci in chains indicates Streptococcus pyogenes; gram-positive cocci in clusters indicate S aureus. Culture and sensitivity results can help the physician choose appropriate antibiotic therapy.
Documentation of a recent streptococcal skin infection in the differential diagnosis of APSGN is accomplished best by obtaining antideoxyribonuclease B (anti-DNase B) and antihyaluronidase (AH) titers. More than 92% of patients with impetigo-associated APSGN have elevated anti-DNase B titers. Patients with impetigo have a poor antistreptolysin O (ASO) serologic response; only 51% of patients with impetigo-associated APSGN develop an increased ASO titer.
Urinalysis is necessary to evaluate for APSGN if the patient develops new-onset edema or hypertension. Hematuria, proteinuria, and cylindruria are indicators of renal involvement.
A potassium hydroxide wet mount may be performed to exclude bullous dermatophyte infection. A Tzanck preparation or viral culture may be performed to exclude herpes simplex infection.
A bacterial culture of the nares may be obtained to determine whether a patient is an S aureus carrier. If the nares culture is negative and the patient has persistent recurrent episodes of impetigo, bacterial cultures should be obtained from the axillae, pharynx, and perineum.
Obtain serum IgM levels in cases of recurrent impetigo in patients with negative S aureus carrier status and no predisposing factors such as a preexisting dermatosis.[26] Serum level determination of IgA, IgM, and IgG, including IgG subclasses, is necessary to rule out other immunodeficiencies.
Histologic Findings
Biopsy may be appropriate in doubtful or refractory cases of impetigo.[10] In bullous impetigo, few or no inflammatory cells are present within the bulla. A polymorphous infiltrate is present in the upper dermis. Acantholysis is noted in the granular layer.
In nonbullous impetigo, a serum crust is present above the epidermis. Neutrophils are common within the crust. In addition, gram-positive cocci are seen. Epidermal spongiosis and a severe dermal infiltrate of neutrophils and lymphoid cells are seen.
Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. Mar 15 2007;75(6):859-64. [Medline].
Moulin F, Quinet B, Raymond J, Gillet Y, Cohen R. [Managing children skin and soft tissue infections]. Arch Pediatr. Oct 2008;15 Suppl 2:S62-7. [Medline].
Hirschmann JV. Impetigo: etiology and therapy. Curr Clin Top Infect Dis. 2002;22:42-51. [Medline].
Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis. Jun 2005;11(6):928-30. [Medline].
Kuniyuki S, Nakano K, Maekawa N, Suzuki S. Topical antibiotic treatment of impetigo with tetracycline. J Dermatol. Oct 2005;32(10):788-92. [Medline].
Treating impetigo in primary care. Drug Ther Bull. Jan 2007;45(1):2-4. [Medline].
Broccardo CJ, Mahaffey S, Schwarz J, et al. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization. J Allergy Clin Immunol. Jan 2011;127(1):186-93, 193.e1-11. [Medline]. [Full Text].
Yamasaki O, Tristan A, Yamaguchi T, et al. Distribution of the exfoliative toxin D gene in clinical Staphylococcus aureus isolates in France. Clin Microbiol Infect. Jun 2006;12(6):585-8. [Medline].
Daskalaki M, Rojo P, Marin-Ferrer M, Barrios M, Otero JR, Chaves F. Panton-Valentine leukocidin-positive Staphylococcus aureus skin and soft tissue infections among children in an emergency department in Madrid, Spain. Clin Microbiol Infect. Jan 2010;16(1):74-7. [Medline].
Geria AN, Schuartz RA. Impetigo Update: New Challenges in the Era of Methicillin Resistance. Cutis. 2010;85(2):65-70.
Geng W, Yang Y, Wu D, et al. Molecular characteristics of community-acquired, methicillin-resistant Staphylococcus aureus isolated from Chinese children. FEMS Immunol Med Microbiol. Apr 2010;58(3):356-62. [Medline].
Liu Y, Kong F, Zhang X, Brown M, Ma L, Yang Y. Antimicrobial susceptibility of Staphylococcus aureus isolated from children with impetigo in China from 2003 to 2007 shows community-associated methicillin-resistant Staphylococcus aureus to be uncommon and heterogeneous. Br J Dermatol. Dec 2009;161(6):1347-50. [Medline].
Loffeld A, Davies P, Lewis A, Moss C. Seasonal occurrence of impetigo: a retrospective 8-year review (1996-2003). Clin Exp Dermatol. Sep 2005;30(5):512-4. [Medline].
Koning S, Verhagen AP, van Suijlekom-Smit LW, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2004;CD003261. [Medline].
Razmjou RG, Willemsen SP, Koning S, et al. Determinants of regional differences in the incidence of impetigo. Environ Res. Jul 2009;109(5):590-3. [Medline].
Spurling G, Askew D, King D, Mitchell GK. Bacterial skin infections--an observational study. Aust Fam Physician. Jul 2009;38(7):547-51. [Medline].
Patrizi A, Raone B, Savoia F, Ricci G, Neri I. Recurrent toxin-mediated perineal erythema: eleven pediatric cases. Arch Dermatol. Feb 2008;144(2):239-43. [Medline].
George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. Jun 2003;53(491):480-7. [Medline]. [Full Text].
Koning S, Verhagen AP, van Suijlekom-Smit LW, Morris A, Butler CC, van der Wouden JC. Interventions for impetigo. Cochrane Database Syst Rev. 2004;CD003261. [Medline].
Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. Nov 15 2005;41(10):1373-406. [Medline].
Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: an update. Int J Dermatol. Apr 2003;42(4):251-5. [Medline].
George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. Jun 2003;53(491):480-7. [Medline]. [Full Text].
Mancini AJ. Bacterial skin infections in children: the common and the not so common. Pediatr Ann. Jan 2000;29(1):26-35. [Medline].
American Academy of Pediatrics. Group A Streptococcal infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, Ill: American Academy of Pediatrics; 2009:616-28.
Ludlam H, Cookson B. Scrum kidney: epidemic pyoderma caused by a nephritogenic Streptococcus pyogenes in a rugby team. Lancet. Aug 9 1986;2(8502):331-3. [Medline].
Belgemen T, Suskan E, Dogu F, Ikinciogullari A. Selective immunoglobulin M deficiency presenting with recurrent impetigo: a case report and review of the literature. Int Arch Allergy Immunol. 2009;149(3):283-8. [Medline].
Sarabi K, Khachemoune A. Tinea capitis: a review. Dermatol Nurs. Dec 2007;19(6):525-9; quiz 530. [Medline].
Popovich D, McAlhany A. Accurately diagnosing commonly misdiagnosed circular rashes. Dermatol Nurs. Aug 2008;20(4):294-300. [Medline].
Gorani A, Oriani A, Cambiaghi S. Seborrheic dermatitis-like tinea faciei. Pediatr Dermatol. May-Jun 2005;22(3):243-4. [Medline].
Hayakawa K, Hirahara K, Fukuda T, Okazaki M, Shiohara T. Risk factors for severe impetiginized atopic dermatitis in Japan and assessment of its microbiological features. Clin Exp Dermatol. Jul 2009;34(5):e63-5. [Medline].
Rashid R, Hymes S. Folliculitis, follicular mucinosis, and papular mucinosis as a presentation of chronic myelomonocytic leukemia. Dermatol Online J. May 15 2009;15(5):16. [Medline].
Scheinfeld N. A Primer In Topical Antibiotics For The Skin And Eyes. J Drugs Dermatol. 2008;7(4):409-415.
Wilkinson RD, Carey WD. Topical mupirocin versus topical neosporin in the treatment of cutaneous infections. Int J Dermatol. Sep 1988;27(7):514-5. [Medline].
Bass JW, Chan DS, Creamer KM, et al. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Pediatr Infect Dis J. Jul 1997;16(7):708-10. [Medline].
Silverberg N, Block S. Uncomplicated skin and skin structure infections in children: diagnosis and current treatment options in the United States. Clin Pediatr (Phila). Apr 2008;47(3):211-9. [Medline].
Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. May 2008;158(5):1077-82. [Medline].
Jacobs MR. Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children. Future Microbiol. Dec 2007;2(6):591-600. [Medline].
Jones RS. Expert advice on erasing the MRSA threat. Pract Dermatol. 2005;34-7.
Woodford N, Afzal-Shah M, Warner M, Livermore DM. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Antimicrob Chemother. Oct 2008;62(4):766-8. [Medline].
Boyd B, Castañar J. Retapamulin. Drugs Future. 2006;31:107.
Oranje AP, Chosidow O, Sacchidanand S, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology. 2007;215(4):331-40. [Medline].
Drug and Therapeutics Bulletin. Retapamulin for impetigo and other infections. Drug Ther Bull. Oct 2008;46(10):76-9. [Medline].
Denton M, O'Connell B, Bernard P, Jarlier V, Williams Z, Henriksen AS. The EPISA study: antimicrobial susceptibility of Staphylococcus aureus causing primary or secondary skin and soft tissue infections in the community in France, the UK and Ireland. J Antimicrob Chemother. Mar 2008;61(3):586-8. [Medline].
O'Neill AJ, Larsen AR, Skov R, Henriksen AS, Chopra I. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol. May 2007;45(5):1505-10. [Medline]. [Full Text].
Laurent F, Tristan A, Croze M, et al. Presence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus in France. J Antimicrob Chemother. Feb 2009;63(2):420-1; author reply 421. [Medline].
Alsterholm M, Flytström I, Bergbrant IM, Faergemann J. Fusidic acid-resistant Staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis. Acta Derm Venereol. 2010;90(1):52-7. [Medline].
Gelmetti C. Local antibiotics in dermatology. Dermatol Ther. May-Jun 2008;21(3):187-95. [Medline].
Langner A, Chu A, Goulden V, Ambroziak M. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. Br J Dermatol. Jan 2008;158(1):122-9. [Medline].
Capizzi R, Landi F, Milani M, Amerio P. Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator-masked, controlled trial. Br J Dermatol. Aug 2004;151(2):481-4. [Medline].
Groner A, Laing-Grayman D, Silverberg NB. Outpatient pediatric community-acquired methicillin-resistant Staphylococcus aureus: a polymorphous clinical disease. Cutis. Feb 2008;81(2):115-22. [Medline].
Bernard P. Management of common bacterial infections of the skin. Curr Opin Infect Dis. Apr 2008;21(2):122-8. [Medline].
Yang LP, Keam SJ. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs. 2008;68(6):855-73. [Medline].
Deshpande LM, Fix AM, Pfaller MA, Jones RN. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis. Apr 2002;42(4):283-90. [Medline].

